As outlined in the scientific reports, the family of oxygenases that are central to the activity of TNA are involved in the hypoxic response involving hypoxia inducible factor. The latter has been termed a master switch for blood vessel growth (angiogenesis) and its control is therefore of enormous potential in the treatment of cardiovascular disease and cancer. Work by the Partners in collaboration with others has led to the identification of the 'angiogenesis oxygenases'. A key element in this work was the structural work generated as part of TNA. This work has attracted very widespread attention and has stimulated new lines of research in many other laboratories worldwide. It has led to the creation of a 'spin-out' company, ReOx, focusing the development of new treatments for ischemic disease